Please login to the form below

I have forgotten my password

Talen

This page shows the latest Talen news and features for those working in and with pharma, biotech and healthcare.

Trial dents confidence in Sangamo’s gene-editing tech

alternative to other methods such as CRISPR and TALEN for in vivo gene editing.

Latest news

Editas CEO exits the CRISPR firm ahead of first clinical trial

Editas is one of several companies striving to develop new therapies based on CRISPR-Cas9 or other technologies – such as zinc finger nucleases (ZFN) or TALEN – that can modify genes in
Sangamo’s first gene-editing trial doesn’t convince investors

TALEN, as a go-to platform for drugs that can modify patients’ genes in vivo.
Sangamo bulks up in cell therapy with TxCell acquisition

Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.
Gilead signs $3bn-plus gene-editing deal with Sangamo

Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.
Altering genes on demand

The introduction of zinc-finger nucleases (ZFNs) and TALE nucleases (TALENs) in the genome engineering toolbox has already allowed gene manipulation in additional higher organisms such as human cells.

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Switzerland: a life sciences hub

cells engineered to display chimeric antigen receptors) and genome editing (ie, CRISPR/Cas, TALEN, ZNF).
2019: CRISPR and therapeutic gene editing comes of age

Before CRISPR, the introduction of zinc-finger nucleases (ZFNs) and TALE nucleases (TALENs) in the genome engineering toolbox has already allowed gene manipulation in additional higher organisms such as human cells. ... TALENs work in a similar way to
Cutting through the noise: CRISPR

But other technologies are still very much in play. Chief among these are zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALEN). ... Cell therapy company Cellectis remains an exponent of TALEN, while Bluebird is using

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story: ...
Working together to achieve better patient pathways: Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.: How design can lead improvement within Pharma...

Email:
Password:

Please login to the form below

Talen

Subscribe to our email news alerts

Quick links